エーザイ、臨床第III相 Clarity AD 試験データを用いた「レカネマブ」の社会的価値について、査読学術専門誌 Neurology and Therapy 誌に掲載 Eisai Mar 20, 2023 10:00 JST Read More
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease Eisai Mar 14, 2023 10:09 HKT/SGT Read More
エーザイ、早期アルツハイマー病治療薬「LEQEMBI(TM)」（レカネマブ）について、米国退役軍人保健局が FDA による迅速承認から 2 カ月で保険適用を開始 Eisai Mar 14, 2023 09:30 JST Read More
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award Eisai Mar 10, 2023 14:04 HKT/SGT Read More
Eisai Certified as a 2023 Health and Productivity Management Outstanding Eisai Mar 09, 2023 08:07 HKT/SGT Read More
エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請（sBLA）が米国FDAに受理され、優先審査に指定 Eisai Mar 06, 2023 10:00 JST Read More
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease Eisai Mar 06, 2023 09:58 HKT/SGT Read More
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan Eisai Mar 02, 2023 09:45 HKT/SGT Read More
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration Eisai Feb 28, 2023 14:28 HKT/SGT Read More
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」の中国における生物ライセンス申請（BLA）が優先審査に指定 Eisai Feb 28, 2023 09:50 JST Read More
Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd Olympus Feb 24, 2023 14:00 HKT/SGT Read More
Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd Olympus Feb 24, 2023 14:00 HKT/SGT Read More
ONERHT Foundation together with Chui Huay Lim Club and Ee Hoe Hean Club raise close to S$500,000 to promote medical care and support for disadvantaged groups ONERHT Foundation Feb 14, 2023 18:00 JST Read More
